RT Journal Article
SR Electronic
T1 The Impact of the Variation of CT Scanner on the Prediction of human papillomavirus (HPV) Association of Oropharyngeal Cancer (OPC) using Radiomic models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.04.21252908
DO 10.1101/2021.03.04.21252908
A1 Reiazi, Reza
A1 Arrowsmith, Colin
A1 Welch, Mattea
A1 Abbas-Aghababazadeh, Farnoosh
A1 Eeles, Christopher
A1 Tadic, Tony
A1 Hope, Andrew J.
A1 Bratman, Scott V.
A1 Haibe-Kains, Benjamin
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252908.abstract
AB Studies have shown that radiomic features are sensitive to the variability of imaging parameters (e.g., scanner model) and one of the major challenges in these studies lies in improving the robustness of quantitative features against the variations in imaging datasets from multi-center studies. Here, we assess the impact of scanner choice on the computed tomography (CT)-derived radiomic features to predict association of oropharyngeal squamous cell carcinoma with human papillomavirus (HPV). This experiment was performed on CT image datasets acquired with two different scanner manufacturers. We demonstrate strong scanner dependency by developing a machine learning model to classify HPV status from radiological images. These experiments revealed the effect of scanner manufacturers on the robustness of the radiomic features, and the extent of this dependency is reflected on the performance of HPV prediction models. The results of this study highlight the importance of implementing an appropriate approach to reduce the impact of imaging parameters on radiomic features and consequently on the machine learning models.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this study was supported by Canadian Institute of Health Research (CIHR) under grant number: 426366 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient data were retrospectively collected from the Princess Margaret Cancer Centre, University Health Network and was approved by the institutional review board (REB 17-5871).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code for all the computation generated during the study are available from the corresponding author on reasonable request.